WO1992018154A1 - Human bone derived insulin like growth factor binding protein - Google Patents
Human bone derived insulin like growth factor binding protein Download PDFInfo
- Publication number
- WO1992018154A1 WO1992018154A1 PCT/US1992/003122 US9203122W WO9218154A1 WO 1992018154 A1 WO1992018154 A1 WO 1992018154A1 US 9203122 W US9203122 W US 9203122W WO 9218154 A1 WO9218154 A1 WO 9218154A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igfbp
- hbd
- igf
- bone
- patient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the portion(s) of hBD-IGFBP protein which bind hydroxyapatite and/or IGF-II may be identified by a variety of methods, such as by treating purified hBD-IGFBP with a protease or a chemical agent to fragment it and determine which fragment is able to bind to labeled IGF-II or hydroxyapatite. Polypeptides may then be synthesized and used as antigen, to inhibit IGF-II or hydroxyapatite-hBD-IGFBP interaction, etc. It should be understood that as used herein, reference to hBD- IGFBP is meant to include the proteins, polypeptides, and fragments thereof unless the context indicates otherwise.
- the invention provides screening procedures for identifying agonists or antagonists of events mediated by the ligand/hBD-IGFBP interaction.
- screening assays may employ a wide variety of formats, depending to some extent on which aspect of the ligand/binding protein interaction is targeted. For example, such assays may be designed to identify compounds which bind to the binding protein and thereby block or inhibit interaction with the IGF-II or hydroxyapatite. Other assays can be designed to identify compounds which can substitute for hBD-IGFBP. Yet other assays can be used to identify compounds which inhibit or facilitate the association of IGF to hBD-IGFBP and thereby mediate the cellular response to IGF.
- hBD-IGFBP Human bone extract was subjected to hydroxyapatite (HA) chromatography in 4 M guanidine HCl as described in Mohan, et al., ibid.
- An IGF-II affinity column was constructed by coupling 250 ⁇ g of IGF-II purified from human bone to cyanogen bromide-activated Sepharose 4B beads.
- the column was then extensively washed with potassium phosphate buffer to completely remove the unbound proteins.
- the bound proteins were eluted with 20-25 ml of 30 mM tris-acetate (pH 7.2)/4 M guanidine-HCl.
- the affinity bound fraction was concentrated in an Amicon cell using a YM 5 membrane and then dialyzed against 20 mM tris-HCl (pH 8.0) buffer.
- the dialyzed affinity bound fraction was applied to a Pharmacia FPLC Mono Q anion exchange column previously equilibrated with the tris-HCl buffer.
- the bound proteins were eluted with a linear gradient from 0-1 M NaCl in 20 mM tris-HCl buffer in 100 min.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4510060A JP2527896B2 (ja) | 1991-04-19 | 1992-04-15 | ヒト骨由来インスリン様成長因子結合タンパク |
AU17844/92A AU658187B2 (en) | 1991-04-19 | 1992-04-15 | Human bone derived insulin like growth factor binding protein |
FI934588A FI934588A (fi) | 1991-04-19 | 1993-10-18 | Insulinlik vaextfaktor bindande protein haerstammande fraon maenniskoben |
KR93703181A KR0129864B1 (en) | 1991-04-19 | 1993-10-19 | Human bore devived insulin like growth factor binding protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68835391A | 1991-04-19 | 1991-04-19 | |
US688,353 | 1991-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992018154A1 true WO1992018154A1 (en) | 1992-10-29 |
Family
ID=24764088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/003122 WO1992018154A1 (en) | 1991-04-19 | 1992-04-15 | Human bone derived insulin like growth factor binding protein |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0580752A4 (fi) |
JP (1) | JP2527896B2 (fi) |
KR (1) | KR0129864B1 (fi) |
AU (1) | AU658187B2 (fi) |
CA (1) | CA2107475A1 (fi) |
CZ (1) | CZ283601B6 (fi) |
FI (1) | FI934588A (fi) |
HU (1) | HUT70297A (fi) |
NO (1) | NO933742L (fi) |
RU (1) | RU2114120C1 (fi) |
WO (1) | WO1992018154A1 (fi) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5407913A (en) * | 1992-12-03 | 1995-04-18 | Celtrix Pharmaceuticals, Inc. | Method and composition for systemic treatment of tissue injury |
US5643867A (en) * | 1992-08-26 | 1997-07-01 | Celtrix Pharmaceuticals, Inc. | Method for treating catabolic conditions |
EP0800530A1 (en) * | 1994-07-20 | 1997-10-15 | Celtrix Pharmaceuticals, Inc. | Igf/igfbp complex for promoting bone formation and for regulating bone remodeling |
US6124259A (en) * | 1993-01-28 | 2000-09-26 | Celtrix Pharmaceuticals, Inc. | Method for treating ophthalmic disorders with IGFBP |
US6500635B1 (en) | 1991-01-08 | 2002-12-31 | Chiron Corporation | Insulin-like growth factor binding protein (IGFBF-5) |
US6903078B1 (en) | 1995-10-11 | 2005-06-07 | Chiron Corporation | Combination PDGF, KGF, IGF, and IGFBP for wound healing |
US8642037B2 (en) | 2001-01-05 | 2014-02-04 | Amgen Fremont Inc. | Antibodies to insulin-like growth factor I receptor |
CN108699127A (zh) * | 2015-12-31 | 2018-10-23 | 西门子医疗保健诊断公司 | 非重组人胰岛素-样生长因子结合蛋白浓缩物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7077229B2 (ja) * | 2015-12-31 | 2022-05-30 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッド | 非組み換えヒトインスリン様成長因子結合タンパク質の濃縮物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642120A (en) * | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
EP0289314A2 (en) * | 1987-04-28 | 1988-11-02 | Roche Diagnostics GmbH | Use of IGF-II in the treatment of bone disorders |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7907958A (nl) * | 1979-10-30 | 1981-06-01 | Wijn Adriaan Jacques De | Kar of onderstel voorzien van opklapbare wielen. |
-
1992
- 1992-04-15 WO PCT/US1992/003122 patent/WO1992018154A1/en not_active Application Discontinuation
- 1992-04-15 CZ CS932190A patent/CZ283601B6/cs not_active IP Right Cessation
- 1992-04-15 AU AU17844/92A patent/AU658187B2/en not_active Ceased
- 1992-04-15 JP JP4510060A patent/JP2527896B2/ja not_active Expired - Lifetime
- 1992-04-15 CA CA002107475A patent/CA2107475A1/en not_active Abandoned
- 1992-04-15 RU RU93058185A patent/RU2114120C1/ru active
- 1992-04-15 HU HU9302942A patent/HUT70297A/hu unknown
- 1992-04-15 EP EP9292910967A patent/EP0580752A4/en not_active Withdrawn
-
1993
- 1993-10-18 FI FI934588A patent/FI934588A/fi unknown
- 1993-10-18 NO NO933742A patent/NO933742L/no not_active Application Discontinuation
- 1993-10-19 KR KR93703181A patent/KR0129864B1/ko not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4642120A (en) * | 1983-03-23 | 1987-02-10 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Repair of cartilage and bones |
EP0289314A2 (en) * | 1987-04-28 | 1988-11-02 | Roche Diagnostics GmbH | Use of IGF-II in the treatment of bone disorders |
Non-Patent Citations (2)
Title |
---|
Proc. Natl. Acad. Sci., Volume 86, issued November 1989, S. MOHAN et al., "Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell-conditioned medium; a potential local regulator of IGF action", see the entire document, particularly the Abstract. * |
See also references of EP0580752A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6500635B1 (en) | 1991-01-08 | 2002-12-31 | Chiron Corporation | Insulin-like growth factor binding protein (IGFBF-5) |
US6906029B2 (en) | 1991-01-08 | 2005-06-14 | Chiron Corporation | Insulin-like growth factor binding protein (IGFBP-5) |
US5643867A (en) * | 1992-08-26 | 1997-07-01 | Celtrix Pharmaceuticals, Inc. | Method for treating catabolic conditions |
US5407913A (en) * | 1992-12-03 | 1995-04-18 | Celtrix Pharmaceuticals, Inc. | Method and composition for systemic treatment of tissue injury |
US6124259A (en) * | 1993-01-28 | 2000-09-26 | Celtrix Pharmaceuticals, Inc. | Method for treating ophthalmic disorders with IGFBP |
EP0800530A1 (en) * | 1994-07-20 | 1997-10-15 | Celtrix Pharmaceuticals, Inc. | Igf/igfbp complex for promoting bone formation and for regulating bone remodeling |
EP0800530A4 (en) * | 1994-07-20 | 1998-12-02 | Celtrix Pharma | IGF / IGFBP COMPLEX FOR PROMOTING BONE TRAINING AND REGULATING BONE REMODELING |
US6017885A (en) * | 1994-07-20 | 2000-01-25 | Celtrix Pharmaceuticals, Inc. | IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling |
US6903078B1 (en) | 1995-10-11 | 2005-06-07 | Chiron Corporation | Combination PDGF, KGF, IGF, and IGFBP for wound healing |
US8642037B2 (en) | 2001-01-05 | 2014-02-04 | Amgen Fremont Inc. | Antibodies to insulin-like growth factor I receptor |
US9234041B2 (en) | 2001-01-05 | 2016-01-12 | Pfizer Inc. | Antibodies to insulin-like growth factor I receptor |
CN108699127A (zh) * | 2015-12-31 | 2018-10-23 | 西门子医疗保健诊断公司 | 非重组人胰岛素-样生长因子结合蛋白浓缩物 |
Also Published As
Publication number | Publication date |
---|---|
JP2527896B2 (ja) | 1996-08-28 |
FI934588A0 (fi) | 1993-10-18 |
KR0129864B1 (en) | 1998-04-09 |
EP0580752A1 (en) | 1994-02-02 |
CZ219093A3 (en) | 1994-12-15 |
RU2114120C1 (ru) | 1998-06-27 |
CA2107475A1 (en) | 1992-10-20 |
AU1784492A (en) | 1992-11-17 |
HU9302942D0 (en) | 1994-01-28 |
AU658187B2 (en) | 1995-04-06 |
HUT70297A (en) | 1995-09-28 |
NO933742L (no) | 1993-10-18 |
CZ283601B6 (cs) | 1998-05-13 |
JPH06501270A (ja) | 1994-02-10 |
EP0580752A4 (en) | 1994-08-24 |
FI934588A (fi) | 1993-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5736511A (en) | Methods for treatment using acid-labile subunit (ALS) of insulin-like growth factor binding protein complex | |
AU623447B2 (en) | Binding protein for insulin-like growth factors | |
JP2648951B2 (ja) | 人体のソマトメジン担体蛋白質サブユニットとこれらの製法 | |
EP0424416B1 (en) | Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex | |
EP0546110B1 (en) | New insulin-like growth factor binding protein igfbp-5 | |
Perkel et al. | An inhibitory insulin-like growth factor binding protein (In-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived In-IGFBP | |
AU658187B2 (en) | Human bone derived insulin like growth factor binding protein | |
Ogasawara et al. | Identification and purification of truncated insulin-like growth factor I from porcine uterus. Evidence for high biological potency | |
WO1992003470A1 (en) | Genetic material encoding igfbp-5 | |
US5453489A (en) | Polypeptide fragments of fibronectin which can modulate extracellular matrix assembly | |
US5919902A (en) | Leptin bound to inter-alphatrypsin inhibitor and uses thereof | |
JPH11506337A (ja) | 骨刺激因子 | |
WO1999049894A1 (en) | Antagonists to growth arrest specific gene 6 to treat insulin-resistant disorders | |
Ogata | Demonstration of pancreatic secretory trypsin inhibitor in serum-free culture medium conditioned by the human pancreatic carcinoma cell line CAPAN-1. | |
US5693754A (en) | Inhibitory binding protein for insulin-like growth factors | |
US7125961B2 (en) | Acid-labile subunit (ALS) of insulin-like growth factor binding protein complex | |
AU638935B2 (en) | Acid-labile subunit (als) of insulin-like-growth factor (igf)binding protein complex | |
US6329500B1 (en) | Transforming growth factor-β binding site | |
US20030027753A1 (en) | Bone stimulating factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
EX32 | Extension under rule 32 effected after completion of technical preparation for international publication | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992910967 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2107475 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1993-2190 Country of ref document: CZ Ref document number: 934588 Country of ref document: FI |
|
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
LE32 | Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b) | ||
ENP | Entry into the national phase |
Ref document number: 1993 137182 Country of ref document: US Date of ref document: 19931112 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1992910967 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1993-2190 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1993-2190 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1992910967 Country of ref document: EP |